Patients

MacroGenics’ Investigational Product Candidates

MacroGenics is a biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases.

MacroGenics and its collaboration partners are conducting clinical studies that explore the use of product candidates developed by MacroGenics in different cancer settings. The product candidates listed below are investigational, in that they are being evaluated in clinical trials and are not yet approved for use by regulatory authorities. Approval by regulatory authorities around the world, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), is required to make our medicine available to the patients. Therefore, our priority is to enroll patients in clinical trials in order to obtain the data required for review and approval by regulatory authorities.

Hematological Malignancies

Acute Myeloid Leukemia (AML) and Myeloid Dysplastic Syndrome (MDS)

MGD006 (CD123 x CD3 DART^® molecule)

Relapsed/refractory B-cell Malignancies (including diffuse-large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL)